B of A Securities Maintains Buy on Avidity Biosciences, Raises Price Target to $54

Benzinga · 06/09 18:04
B of A Securities analyst Geoff Meacham maintains Avidity Biosciences (NASDAQ:RNA) with a Buy and raises the price target from $48 to $54.